LEADER 03387nam 2200613Ia 450 001 9910955647403321 005 20251116221324.0 010 $a1-61209-863-0 035 $a(CKB)2560000000070422 035 $a(EBL)3019220 035 $a(SSID)ssj0000467285 035 $a(PQKBManifestationID)12124009 035 $a(PQKBTitleCode)TC0000467285 035 $a(PQKBWorkID)10490125 035 $a(PQKB)11132255 035 $a(MiAaPQ)EBC3019220 035 $a(Au-PeEL)EBL3019220 035 $a(CaPaEBR)ebr10663028 035 $a(OCoLC)699510269 035 $a(BIP)28374837 035 $a(EXLCZ)992560000000070422 100 $a20091130d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBiomaterials in blood-contacting devices $ecomplications and solutions /$fMeng-Jiy Wang and Wei-Bor Tsai 205 $a1st ed. 210 $aNew York $cNova Science Publishers$dc2010 215 $a1 online resource (89 p.) 225 1 $aBiomaterials--properties, production and devices series 300 $aDescription based upon print version of record. 311 08$a1-60876-784-1 320 $aIncludes bibliographical references and index. 327 $aBlood components involved in hemostasis and thrombosis -- Blood-contacting devices and materials -- Blood-materials interactions -- Surface modification for improving blood compatibility. 330 $aAll blood-contacting medical devices in use today are subjected to some degree poorer blood compatibility than the native artery. Hemostatic mechanism, arresting bleeding from injured blood vessels, induces platelet adhesion and activation onto artificial biomaterials, which leads to undesirable outcomes such as blood clotting at the site of the implant, continual shedding of thrombi, and depletion of platelets from the blood stream. Such complications have hampered the clinical success of blood contacting devices, limiting the patent of small-diameter vascular grafts and making necessary the use of anticoagulants in patients undergoing extracorporeal bypass or synthetic heart valve implantation. Therefore, development of non-thrombogenic biomaterials is in great need for blood contacting devices. The current approaches mainly focus on surface modifications with biological anticoagulants such as heparin, or anti-fouling molecules like poly(ethylene oxide). In this review, the authors first introduce the blood components involved in hemostasis and thrombosis, followed by the common biomaterials applied in blood-contacting devices. Next, the complications induced by the interactions between blood and biomaterials are briefly addressed. Finally, the commonly used techniques for improving biomaterials' hemocompatibility are expatiated. 410 0$aBiomaterials--properties, production, and devices series. 606 $aPolymers in medicine 606 $aThrombosis 606 $aBiocompatibility 615 0$aPolymers in medicine. 615 0$aThrombosis. 615 0$aBiocompatibility. 676 $a610.28/4 700 $aWang$b Meng-Jiy$01864539 701 $aTsai$b Wei-Bor$f1967-$01864540 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910955647403321 996 $aBiomaterials in blood-contacting devices$94471385 997 $aUNINA